Effect of resmetirom or placebo in NASH (MASH) fibrosis patients with<5% or≥5% weight loss and/or on baseline GLP-1 therapy in the MAESTRO-NASH 52-week serial liver biopsy study

¹ University Medical Center of Johannes Gutenburg University Mainz, and Saarland University Medical Center, Homburg, Metabolic Liver Research Program, I. Department of Medicine (Gutenburg) and Department of Internal Medicine II (Saarland), Mainz, Germany